Xencor, Inc. (XNCR)

Market Cap	832.86M
Revenue (ttm)	110.49M
Net Income (ttm)	-232.62M
Shares Out	70.46M
EPS (ttm)	-3.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	771,313
Open	12.91
Previous Close	12.95
Day's Range	11.64 - 13.17
52-Week Range	11.64 - 27.24
Beta	0.74
Analysts	Strong Buy
Price Target	34.13 (+188.75%)
Earnings Date	May 8, 2025

About XNCR

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 3, 2013
• Employees: 250
• Stock Exchange: NASDAQ
• Ticker Symbol: XNCR
• Website: https://www.xencor.com

Financial Performance

In 2024, Xencor's revenue was $110.49 million, a decrease of -36.72% compared to the previous year's $174.62 million. Losses were -$232.62 million, 74.7% more than in 2023.

Analyst Forecast

According to 8 analysts, the average rating for XNCR stock is "Strong Buy." The 12-month stock price forecast is $34.13, which is an increase of 188.75% from the latest price.

Price Target

$34.13

(188.75% upside)

Analyst Consensus: Strong Buy